Posts

GSK to license Hutchmed cancer drug for $110 million upfront

on

Lilly to Pay Up to $370M for OmniAb Collaboration

on

AstraZeneca seals near $1.8B renal disease pact with CSPC

on

Ipsen acquires Kartos for $1.75B to add Jakafi combo therapy navtemadlin in myelofibrosis

on

Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm

on

Lilly allies with BioArctic

on

Servier inks up to $2.65B buyout of Edgewise's muscular dystrophy unit to boost neurology pipeline

on

Pfizer signs up to $10.5B deal with Innovent for 12 early‑stage cancer drugs from China's biotech hub

on

Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

on

Roche Pays $55M Upfront to Manifold Bio in $2B+ Deal for AI-Guided Next-Gen Brain Shuttles

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on

Roche Inks $80M Upfront Deal for Hansoh's Cancer ADC HS-20110

on

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

on

Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707

on